Results 101 to 110 of about 302,285 (314)

The economic burden of TNFα inhibitors and other biologic treatments in Norway

open access: yes, 2011
Jan Norum1, Wenche Koldingsnes2, Torfinn Aanes3, Margaret Aarag Antonsen4, Jon Florholmen5, Masahide Kondo61Northern Norway Regional Health Authority, Bodø, Norway; 2Department of Rheumatology, University Hospital of North Norway, Troms& ...
Jan Norum   +3 more
core  

The Biologic Syndrome of Frailty in Heart Failure

open access: yes, 2014
As we continue to care for an older and sicker end-stage heart failure population, it has become challenging to evaluate patients based on current risk scores that mainly focus on subjective symptoms and patient disability. For generations, geriatricians
Rita Jermyn, Snehal Patel
core   +1 more source

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan

open access: yes, 2016
Jörg Mahlich,1,2 Rosarin Sruamsiri1,3 1Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan; 2Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany; 3Center of Pharmaceutical ...
Mahlich J, Sruamsiri R
core  

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

open access: yesOpen Access Rheumatology: Research and Reviews, 2018
James R O’Dell,1 Stanley B Cohen,2 J Carter Thorne,3 Joel Kremer4 1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine ...
O’Dell JR   +3 more
doaj  

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

open access: yesFEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens   +8 more
wiley   +1 more source

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

open access: yes, 2018
Laura Niccoli,1 Carlotta Nannini,1 Corrado Blandizzi,2 Stefania Mantarro,2 Marta Mosca,3 Ombretta Di Munno,3 Delia Goletti,4 Maurizio Benucci,5 Francesca Li Gobbi,5 Emanuele Cassarà,1 Olga Kaloudi,1 Fabrizio Cantini1 1Department of ...
Mantarro S   +11 more
core  

Reconstructing enzyme evolution by protein engineering

open access: yesFEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler   +2 more
wiley   +1 more source

Decoding the dynamic extracellular matrix in cancer—3D models and bioscaffolds rewire the rules of tumor progression

open access: yesFEBS Letters, EarlyView.
Cancer progression is regulated by the dynamic matrix code of the tumor microenvironment, which influences cellular behavior and disease development. Importantly, matrix remodeling in three‐dimensional cancer models more accurately reflects in vivo conditions compared to conventional two‐dimensional systems.
Sylvia Mangani   +3 more
wiley   +1 more source

Biologic targeting in the treatment of inflammatory bowel diseases [PDF]

open access: yes, 2009
Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi PorroChair of Gastroenterology, “L. Sacco” University Hospital, Milan, ItalyAbstract: The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive ...
Gabriele Bianchi Porro   +5 more
core  

Home - About - Disclaimer - Privacy